TECN: Resilient Demand And Share Repurchase Program Will Drive Shareholder Value

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

16 Mar 25

Updated

30 Nov 25

Views

52

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-35.4%

7D

0.9%

Loading

1Y

-35.4%

7D

0.9%

You can edit this narrative until Dec 1 10:05 AM. Then, changes will post as Updates.

Author's Valuation

CHF 202.4837.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 30 Nov 25

TECN: Efficiency Gains And Market Recovery Will Drive Forward Earnings Improvements

Analysts have reduced their price target for Tecan Group from CHF 177 to CHF 170. They cited revised market assumptions and modest adjustments to key financial forecasts as reasons for this change.

Shared on 16 Nov 25

Fair value Decreased 1.70%

TECN: Automation Demand And Partnerships Will Drive Earnings Recovery After 2026

Tecan Group: Analyst Price Target Reduced on Updated Outlook Analysts have lowered their fair value estimate for Tecan Group from CHF 205.98 to CHF 202.48. They cited slightly higher discount rates and tempered expectations for revenue growth and profit margins as reasons for the change.

Shared on 01 Nov 25

Fair value Decreased 0.60%

The analyst price target for Tecan Group has been revised downward from CHF 177 to CHF 170. Analysts cite slightly softer revenue growth expectations and a modest increase in the discount rate in their updated assessments.

Shared on 18 Oct 25

Fair value Decreased 3.94%

Tecan Group's updated analyst fair value price target has been revised downward from CHF 215.73 to CHF 207.23. This change reflects cautious analyst views amid slower revenue growth and tightened profit margin expectations.

Shared on 04 Oct 25

Fair value Decreased 2.15%

Analysts have adjusted their price target for Tecan Group downward, reducing the fair value estimate from CHF 220.47 to CHF 215.73. This change is due to a slight increase in the discount rate, although forecasts for revenue growth and profit margins have improved.

Shared on 05 Sep 25

Analysts have lowered their outlook for Tecan Group due to concerns over near-term margin pressure, cautious end-market demand, and delayed recovery in key segments, though the consensus price target remained unchanged at CHF220.47. Analyst Commentary Cautious sentiment due to anticipation of "soft" first-half financial results impacting near-term performance.

Shared on 01 May 25

Fair value Decreased 7.95%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

Fair value Decreased 0.083%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 6.53%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

CHF 202.48

37.0% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

6.59%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

5.00%

Calculation

CHF 109.45m

Earnings '28

x

27.03x

PE Ratio '28

=

CHF 2.96b

Market Cap '28

CHF 2.96b

Market Cap '28

/

12.62m

No. shares '28

=

CHF 234.32

Share Price '28

CHF 234.32 Share Price '28

Discounted to 2025 @ 4.99% p.a.

=

CHF 202.45

Fair Value '25